ARA-290 Dosage Guide: How Much Should You Take? (2026)
Key Takeaways
- Standard Dosage Range: ARA-290 is typically administered at doses ranging from 4 mg to 8 mg, depending on the therapeutic goal and patient response.
- Administration Method: Primarily administered via subcutaneous injection due to its bioavailability and targeted delivery.
- Typical Cycle Length: Treatment cycles can vary from 4 to 12 weeks, with adjustments based on individual response and clinical objectives.
- Regulatory Status: ARA-290 is not FDA-approved for therapeutic use; it is available for research purposes only.
- Medical Supervision: Due to its research status, ARA-290 should be used under the guidance of a qualified healthcare provider.
How ARA-290 Works in the Body
ARA-290 is a synthetic peptide derived from the B-helix domain of erythropoietin, designed to interact with the EPOR–CD131 receptor complex. This interaction activates the innate repair receptor (IRR) pathway, promoting tissue protection without stimulating erythropoiesis. The specificity of ARA-290 for this receptor complex is crucial in its therapeutic applications, particularly in modulating inflammatory responses and protecting neural tissues.
The pharmacokinetic properties of ARA-290, such as its half-life and bioavailability, significantly impact dosing decisions. ARA-290 exhibits a relatively short half-life, necessitating frequent administration to maintain therapeutic levels. Its bioavailability is optimal when administered subcutaneously, allowing for direct absorption into the bloodstream.
Clinical studies have explored ARA-290's efficacy in various conditions. For instance, a study published in Molecular Medicine (PMID 25387363) demonstrated its potential in improving metabolic control and neuropathic symptoms in type 2 diabetes patients. Similarly, research published in Molecular Pain (PMID 24529189) highlighted its ability to provide long-term relief of neuropathic pain.
"ARA-290, a nonerythropoietic peptide engineered from erythropoietin, interacts selectively with the innate repair receptor that mediates tissue protection." — Molecular Medicine (PMID 25387363)
Standard ARA-290 Dosage Ranges (By Form)
Subcutaneous Administration
- Dosage Range: 4 mg to 8 mg per administration
- Frequency: Typically administered once daily
- Bioavailability: High, due to direct absorption into the bloodstream
- Commonality: Subcutaneous injection is the preferred form due to its efficacy and ease of use.
Intramuscular Administration
- Dosage Range: Similar to subcutaneous, but less commonly used
- Frequency: Once daily or as directed by a healthcare provider
- Bioavailability: Slightly lower than subcutaneous administration
Oral and Other Forms
Currently, ARA-290 is primarily available as a lyophilized powder for research use, with subcutaneous injection being the most common administration route. Oral and other forms are not widely utilized due to reduced bioavailability and lack of clinical validation.
ARA-290 Dosage by Use Case
Neuropathic Pain Management
- Typical Dosage Range: 4 mg to 6 mg subcutaneously
- Administration Method: Subcutaneous injection
- Cycle Length: 8 to 12 weeks
- Study Reference: A study in Molecular Pain (PMID 24529189) supports its use for neuropathic pain relief.
Inflammation Modulation
- Typical Dosage Range: 4 mg to 8 mg subcutaneously
- Administration Method: Subcutaneous injection
- Cycle Length: 4 to 8 weeks
- Study Reference: Research in Brain, Behavior, and Immunity (PMID 34343617) explores its role in modulating inflammation.
Metabolic Control in Diabetes
- Typical Dosage Range: 4 mg subcutaneously
- Administration Method: Subcutaneous injection
- Cycle Length: 12 weeks
- Study Reference: Molecular Medicine (PMID 25387363) highlights its efficacy in metabolic control.
How Long Should You Take ARA-290?
The duration of ARA-290 therapy depends on the specific therapeutic goal and individual patient response. Typical treatment cycles range from 4 to 12 weeks. During the initial week, patients may begin to notice subtle improvements, with more pronounced effects emerging between weeks 2 to 4. By week 6 and beyond, many patients report significant symptom relief.
Tapering off ARA-290 is generally not required due to its short half-life. However, discontinuation should be managed by a healthcare provider to monitor any potential return of symptoms.
Administration Protocol: How to Take ARA-290
Injection Technique
- Needle Gauge: Use a 27-30 gauge needle for subcutaneous injections.
- Injection Sites: Rotate between the abdomen, thigh, and upper arm to prevent tissue damage.
- Rotation Schedule: Rotate injection sites daily to minimize local irritation and improve absorption.
Storage Requirements
- Temperature: Store lyophilized powder at 2-8°C (36-46°F).
- Light Sensitivity: Protect from light to maintain stability.
- Reconstituted Stability: Use reconstituted solution within 24 hours if stored at room temperature.
Reconstitution Instructions
For detailed reconstitution instructions, refer to our reconstitution guide.
Administration Process
- Preparation: Wash hands and gather all necessary supplies.
- Reconstitution: Mix the lyophilized powder with the appropriate diluent.
- Injection: Clean the injection site with an alcohol swab, pinch the skin, and inject at a 45-degree angle.
- Post-Injection: Apply gentle pressure with a cotton ball or gauze.
Stacking ARA-290 for Better Results
ARA-290 and BPC-157
- Combination: ARA-290 (4 mg) with BPC-157 (250 mcg)
- Dosing Synergy: Enhances tissue repair and reduces inflammation
- Common Protocols: Used in protocols for sports injuries and chronic pain management
- Link: BPC-157
